574 related articles for article (PubMed ID: 28098725)
1. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
[TBL] [Abstract][Full Text] [Related]
2. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
3. Fluorescein Leakage and Optical Coherence Tomography Features of Choroidal Neovascularization Secondary to Pathologic Myopia.
Battaglia Parodi M; Iacono P; Romano F; Bandello F
Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):3175-3180. PubMed ID: 30025121
[TBL] [Abstract][Full Text] [Related]
4. Microvasculature Changes of Myopic Choroidal Neovascularization and the Predictive Value of Feeder Vessel Disappearance after Ranibizumab Treatment Revealed Using Optical Coherence Tomography Angiography.
Giorno P; Iacono P; Scarinci F; Di Renzo A; Varano M; Parravano M
Ophthalmologica; 2020; 243(4):263-270. PubMed ID: 31838464
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
[TBL] [Abstract][Full Text] [Related]
6. CORRESPONDENCE OF LEAKAGE ON FLUORESCEIN ANGIOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY PARAMETERS IN DIAGNOSIS AND MONITORING OF MYOPIC CHOROIDAL NEOVASCULARIZATION TREATED WITH BEVACIZUMAB.
Battaglia Parodi M; Iacono P; Bandello F
Retina; 2016 Jan; 36(1):104-9. PubMed ID: 26166803
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry.
Gabrielle PH; Nguyen V; Creuzot-Garcher C; Miguel L; Alforja S; Sararols L; Casaroli-Marano RP; Zarranz-Ventura J; Gillies M; Arnold J; Barthelmes D
Acta Ophthalmol; 2022 Feb; 100(1):e288-e296. PubMed ID: 33960115
[TBL] [Abstract][Full Text] [Related]
8. Optical coherence tomography angiography in myopic choroidal neovascularization after intravitreal ranibizumab.
Cennamo G; Amoroso F; Schiemer S; Velotti N; Alfieri M; de Crecchio G
Eur J Ophthalmol; 2019 Mar; 29(2):239-243. PubMed ID: 29991290
[TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns for Myopic Choroidal Neovascularization in the United States: Analysis of the IRIS Registry.
Willis J; Morse L; Vitale S; Parke DW; Rich WL; Lum F; Cantrell RA
Ophthalmology; 2017 Jul; 124(7):935-943. PubMed ID: 28372860
[TBL] [Abstract][Full Text] [Related]
10. FIVE-YEAR OUTCOMES OF INTRAVITREAL INJECTION OF RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION.
Wu TT; Kung YH
Retina; 2017 Nov; 37(11):2056-2061. PubMed ID: 28590318
[TBL] [Abstract][Full Text] [Related]
11. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization.
Mandal S; Venkatesh P; Sampangi R; Garg S
Eur J Ophthalmol; 2007; 17(4):620-6. PubMed ID: 17671940
[TBL] [Abstract][Full Text] [Related]
13. Outcome Predictors of SD-OCT-Driven Intravitreal Ranibizumab in Choroidal Neovascularization due to Myopia.
Guichard MM; Peters G; Tuerksever C; Pruente C; Hatz K
Ophthalmologica; 2020; 243(2):154-162. PubMed ID: 31387095
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
15. Retinal pigmental epithelium elevation and external limiting membrane interruption in myopic choroidal neovascularization: correlation with activity.
Ding X; Zhan Z; Sun L; Yang Y; Li S; Zhang A; Luo X; Lu L
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1831-1837. PubMed ID: 29982899
[TBL] [Abstract][Full Text] [Related]
16. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.
Wolf S; Balciuniene VJ; Laganovska G; Menchini U; Ohno-Matsui K; Sharma T; Wong TY; Silva R; Pilz S; Gekkieva M;
Ophthalmology; 2014 Mar; 121(3):682-92.e2. PubMed ID: 24326106
[TBL] [Abstract][Full Text] [Related]
17. Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.
Cohen SY; Nghiem-Buffet S; Grenet T; Dubois L; Ayrault S; Fajnkuchen F; Delahaye-Mazza C; Quentel G; Tadayoni R
Jpn J Ophthalmol; 2015 Jan; 59(1):36-42. PubMed ID: 25416566
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.
Ikuno Y; Sayanagi K; Soga K; Sawa M; Tsujikawa M; Gomi F; Tano Y
Am J Ophthalmol; 2009 Jan; 147(1):94-100.e1. PubMed ID: 18774550
[TBL] [Abstract][Full Text] [Related]
19. Structural and optical coherence tomography angiography in myopic choroidal neovascularization: Agreement with conventional fluorescein angiography.
Iacono P; Giorno P; Varano M; Parravano M
Eur J Ophthalmol; 2021 Jan; 31(1):149-157. PubMed ID: 31619075
[TBL] [Abstract][Full Text] [Related]
20. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization.
Matsuo M; Honda S; Matsumiya W; Kusuhara S; Tsukahara Y; Negi A
Eur J Ophthalmol; 2012; 22(2):210-5. PubMed ID: 21534251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
